Wednesday - November 18, 2026
Ropes and Gray: OBI Pharma Enters Licensing Agreement With Novartis for Next-Generation Antibody-Drug Conjugates Worth Over $2 Billion
November 18, 2026
BOSTON, Massachusetts, Nov. 18 -- Ropes and Gray, a law firm, posted the following news:

* * *

OBI Pharma Enters Licensing Agreement with Novartis for Next-Generation Antibody-Drug Conjugates Worth Over $2 Billion

November 17, 2026

Ropes & Gray advised Taiwan-based OBI Pharma in a collaboration and license agreement with Novartis Pharma AG in a transaction worth over $2 billion announced on November 13.

Under the agreement, Nov . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products